In areal-world study, 39 patients with EGFR-mutated NSCLC received the innovative re-challenge of furmonertinib (160 mg/d) after resistance to osimertinib or aumolertinib (Table 1) (Qi et al., 2023). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.